WHAT IS CLAIMED IS:

1. An analgesic/anti-inflammatory pharmaceutical

dosage form which comprises an effective amount of an active

3 ingredient selected from the group consisting of racemic 5-

4 benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, of the

5 formula

6 7 8 СООН

9 10 11

12 optically active forms thereof and pharmaceutically acceptable

13 salts thereof, in combination with a pharmaceutically

14 acceptable excipient or diluent, said dosage form being an

15 intranasally administrable dosage form.

1 2. The dosage form of claim 1 comprising 0.5-40 mg 2 of said active ingredient.

1 3. The dosage form of claim 2 comprising 2-20 mg of 2 said active ingredient.

1 4. The dosage form of claim 1 comprising 5-20% of 2 said active ingredient (weight/volume).

1 5. The dosage form of claim 1 in a single-dose 2 form.

1 6. The dosage form of claim 1 in the form of a 2 solution or suspension.

7. The dosage form of claim 1 containing 15% of
 2 said active ingredient.

1 8. The dosage form of claim 1 wherein said 2 excipient comprises a bioadhesive.

- 1 9. The dosage form of claim 1 wherein said
- 2 excipient comprises a polymer that dissolves vehicle viscosity
- 3 based on temperature change, to increase said viscosity at body
- 4 temperature.
- 1 10. The dosage form of claim 1 further comprising as
- 2 an excipient an intranasal absorption promoter.

3

- 1 11. The dosage form of claim 10 wherein said
- 2 promoter is selected from the group consisting of POE (9)
- 3 lauryl alcohol and sodium glycocholate and lysophosphatidyl
- 4 choline.

5

- 1 12. A method for the treatment of inflammatory
- 2 processes and pain of a traumatic or pathologic origin, which
- 3 comprises the administration by the intranasal route of an
- 4 effective amount of the active ingredient 5-benzoyl-2,3-
- 5 dihydro-lH-pyrrolizine-l-carboxylic acid, in a racemic or
- 6 optically active form or in the form of a pharmaceutically
- 7 acceptable salt.
- 1 13. A method according to claim 8 wherein said
- 2 effective amount is within the range of 0.5-40 mg.
- 1 14. A method according to claim 8 wherein said
- 2 effective amount is within the range of 5-30 mg.
- 1 15. A method according to claim 8 wherein said
- 2 effective amount is within the range of 5-20% (weight/volume).
- 1 16. A method according to claim 8 wherein said
- 2 effective amount is within the range of 15% (weight/volume).
- 1 17. A method for the treatment of inflammatory
- 2 processes and pain of a traumatic or pathologic origin which

```
comprises the administration by the intranasal route of a dosage form according to claim 1.

18. A method according to claim 17 wherein said mammal is a human and wherein said effective amount is sufficient to generate a plasma concentration of 5-benzoyl-2,3-4 dihydro-1H-pyrrolizine-1-carboxylic acid within the range between 0.3 and 5 mg/liter of plasma.
```